J&J Grabs Swiss Rare Drug Co. Actelion In $30B Cash Deal
Johnson & Johnson agreed Thursday to buy Swiss rare drug maker Actelion Ltd. in an all-cash, $30 billion deal that gives the pharmaceutical giant access to the Swiss company's specialty high...To view the full article, register now.
Already a subscriber? Click here to view full article